These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 33798116)

  • 21. Stability of gabapentin in extemporaneously compounded oral suspensions.
    Friciu M; Roullin VG; Leclair G
    PLoS One; 2017; 12(4):e0175208. PubMed ID: 28414771
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Stability of acetazolamide in suspension compounded from tablets.
    Alexander KS; Haribhakti RP; Parker GA
    Am J Hosp Pharm; 1991 Jun; 48(6):1241-4. PubMed ID: 1858804
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Stability of flecainide acetate in an extemporaneously compounded oral suspension.
    Wiest DB; Garner SS; Pagacz LR; Zeigler V
    Am J Hosp Pharm; 1992 Jun; 49(6):1467-70. PubMed ID: 1529992
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Stability of extemporaneously prepared moxifloxacin oral suspensions.
    Hutchinson DJ; Johnson CE; Klein KC
    Am J Health Syst Pharm; 2009 Apr; 66(7):665-7. PubMed ID: 19299374
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Stability of extemporaneously prepared cinacalcet oral suspensions.
    Thomson K; Hutchinson DJ; Chablani L
    Am J Health Syst Pharm; 2018 May; 75(9):e236-e240. PubMed ID: 29691267
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Stability of codeine phosphate in an extemporaneously compounded syrup.
    Dentinger PJ; Swenson CF
    Am J Health Syst Pharm; 2007 Dec; 64(24):2569-73. PubMed ID: 18056945
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Stability of isradipine in an extemporaneously compounded oral liquid.
    MacDonald JL; Johnson CE; Jacobson P
    Am J Hosp Pharm; 1994 Oct; 51(19):2409-11. PubMed ID: 7847406
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Stability of extemporaneously prepared rifaximin oral suspensions.
    Cober MP; Johnson CE; Lee J; Currie K
    Am J Health Syst Pharm; 2010 Feb; 67(4):287-9. PubMed ID: 20133533
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Stability of an extemporaneously compounded baclofen oral liquid.
    Johnson CE; Hart SM
    Am J Hosp Pharm; 1993 Nov; 50(11):2353-5. PubMed ID: 8266961
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Stability of extemporaneously prepared glycopyrrolate oral suspensions.
    Cober MP; Johnson CE; Sudekum D; Penprase K
    Am J Health Syst Pharm; 2011 May; 68(9):843-5. PubMed ID: 21515869
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Stability of ursodiol 25 mg/mL in an extemporaneously prepared oral liquid.
    Mallett MS; Hagan RL; Peters DA
    Am J Health Syst Pharm; 1997 Jun; 54(12):1401-4. PubMed ID: 9194984
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Stability of an extemporaneously prepared alcohol-free phenobarbital suspension.
    Cober MP; Johnson CE
    Am J Health Syst Pharm; 2007 Mar; 64(6):644-6. PubMed ID: 17353574
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Stability of Diazoxide in Extemporaneously Compounded Oral Suspensions.
    Friciu M; Zaraa S; Roullin VG; Leclair G
    PLoS One; 2016; 11(10):e0164577. PubMed ID: 27727306
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Stability of itraconazole in an extemporaneously compounded oral liquid.
    Jacobson PA; Johnson CE; Walters JR
    Am J Health Syst Pharm; 1995 Jan; 52(2):189-91. PubMed ID: 12879547
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Stability of flucytosine in an extemporaneously compounded oral liquid.
    Wintermeyer SM; Nahata MC
    Am J Health Syst Pharm; 1996 Feb; 53(4):407-9. PubMed ID: 8673661
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Stability of tacrolimus in an extemporaneously compounded oral liquid.
    Jacobson PA; Johnson CE; West NJ; Foster JA
    Am J Health Syst Pharm; 1997 Jan; 54(2):178-80. PubMed ID: 9117806
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Stability of ursodiol in an extemporaneously compounded oral liquid.
    Johnson CE; Nesbitt J
    Am J Health Syst Pharm; 1995 Aug; 52(16):1798-1800. PubMed ID: 8528836
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Stability of extemporaneously prepared oxandrolone oral suspensions.
    Johnson CE; Cober MP; Hawkins KA; Julian JD
    Am J Health Syst Pharm; 2011 Mar; 68(6):519-21. PubMed ID: 21378300
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Stability of extemporaneously prepared sodium phenylbutyrate oral suspensions.
    Caruthers RL; Johnson CE
    Am J Health Syst Pharm; 2007 Jul; 64(14):1513-5. PubMed ID: 17617502
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Stability of lamotrigine in two extemporaneously prepared oral suspensions at 4 and 25 degrees C.
    Nahata MC; Morosco RS; Hipple TF
    Am J Health Syst Pharm; 1999 Feb; 56(3):240-2. PubMed ID: 10030509
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.